These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22948968)

  • 21. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.
    Hori H; Kudoh T; Nishimura S; Oda M; Yoshida M; Hara J; Tawa A; Usami I; Tanizawa A; Yumura-Yagi K; Kato K; Kobayashi R; Komada Y; Matsuo K; Horibe K;
    Int J Clin Oncol; 2017 Apr; 22(2):387-396. PubMed ID: 27858183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
    Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
    Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Importance of anthracyclines in infants in the treatment of acute lymphoblastic and non-lymphoblastic leukemias].
    Leverger G; Bancillon A; Schaison G
    Pathol Biol (Paris); 1987 Jan; 35(1):87-90. PubMed ID: 3550617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study.
    Frost BM; Eksborg S; Björk O; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Lönnerholm G
    Med Pediatr Oncol; 2002 May; 38(5):329-37. PubMed ID: 11979457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
    Gardner RA; Thomson B; Hawkins DS
    Pediatr Blood Cancer; 2013 Feb; 60(2):338-9. PubMed ID: 23015453
    [No Abstract]   [Full Text] [Related]  

  • 29. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
    Escherich G; Horstmann MA; Zimmermann M; Janka-Schaub GE;
    Leukemia; 2010 Feb; 24(2):298-308. PubMed ID: 20016530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
    Marie JP; Thevenin D; Zittoun R
    Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
    Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
    Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of doxorubicin and daunorubicin on the activity of acetylcholinesterase in acute lymphoblastic leukamia.
    Niazi IU; Tariq SA; Ali A
    J Ayub Med Coll Abbottabad; 2011; 23(2):45-7. PubMed ID: 24800340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-asparaginase: long-term results of a randomized trial of the effect of additional 3 doses during consolidation treatment in the Indonesian WK-ALL-2000 protocol.
    Widjajanto PH; Sumadiono S; Purwanto I; Sutaryo S; Veerman AJ
    J Pediatr Hematol Oncol; 2013 Nov; 35(8):597-602. PubMed ID: 23389497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.
    Robinson KM; Yang W; Karol SE; Kornegay N; Jay D; Cheng C; Choi JK; Campana D; Pui CH; Wood B; Borowitz MJ; Gastier-Foster J; Larsen EC; Winick N; Carroll WL; Loh ML; Raetz EA; Hunger SP; Devidas M; Mardis ER; Fulton RS; Relling MV; Jeha S
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27681. PubMed ID: 30848065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.